Investing.com - Biora Therapeutics (NASDAQ: BIOR) reported fourth quarter EPS of $-1.590, $1.52 worse than the analyst estimate of $-0.070. Revenue for the quarter came in at $14K versus the consensus estimate of $90K.
Biora Therapeutics's stock price closed at $3.350. It is up 2.130% in the last 3 months and down -81.890% in the last 12 months.
Biora Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Biora Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Biora Therapeutics's Financial Health score is "weak performance".
Check out Biora Therapeutics's recent earnings performance, and Biora Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar